Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Nab-Paclitaxel in Preoperative HR+ Breast Cancer
NCT02999477Phase 1Completed
- Sponsor
- Adrienne G. Waks
- Start
- Feb 2017
- Primary completion
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pembrolizumab in breast cancer (2 arms), sponsored by Adrienne G. Waks. Primary endpoint: Change in the Biomarker (PD-L1) Expression at 2 weeks. Started Feb 2017; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02999477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02999477.